Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eledon Pharmaceuticals, Inc. (ELDN : NSDQ)

• Company Description    Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $2.54 Daily Weekly Monthly 20 Day Moving Average: 642,976 shares Shares Outstanding: 59.88 (millions) Market Capitalization: $152.10 (millions) Beta: -0.12 52 Week High: $5.54 52 Week Low: $2.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.31% -4.07% 12 Week -8.63% -17.05% Year To Date -38.35% -44.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19900 MACARTHUR BOULEVARD SUITE 250 - IRVINE,CA 92612 USA ph: 949-238-8090 fax: - investors@eledon.com http://www.eledon.com

• General Corporate Information    Officers David-Alexandre C. Gros - Chief Executive Officer and Director Keith A. Katkin - Chairman Paul Little - Chief Financial Officer Jan Hillson - Director James Robinson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28617K101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 59.88 Most Recent Split Date: 10.00 (0.06:1) Beta: -0.12 Market Capitalization: $152.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.02 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 59.38% vs. Previous Quarter: -62.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -92.51 03/31/25 - -126.44 12/31/24 - -220.37 ROA 06/30/25 - -38.31 03/31/25 - -41.62 12/31/24 - -51.50 Current Ratio 06/30/25 - 8.12 03/31/25 - 13.90 12/31/24 - 12.41 Quick Ratio 06/30/25 - 8.12 03/31/25 - 13.91 12/31/24 - 12.42 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.84 03/31/25 - 0.98 12/31/24 - 1.05 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©